MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Rating of “Hold” by Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT) has been given an average rating of “Hold” by the five ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $35.00.

INKT has been the topic of several research analyst reports. Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings cut MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a report on Monday, May 18th.

MiNK Therapeutics Stock Performance

INKT opened at $10.87 on Monday. The firm’s fifty day moving average is $10.93 and its two-hundred day moving average is $11.47. The firm has a market cap of $54.13 million, a PE ratio of -3.83 and a beta of 0.47. MiNK Therapeutics has a twelve month low of $6.80 and a twelve month high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20. Equities analysts forecast that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

Institutional Trading of MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC boosted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the SEC. 2.87% of the stock is owned by institutional investors.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.